

Special Issue

Development and Drug Delivery in Epigenetic Therapy

Message from the Guest Editor

We will be serving as for this very interesting Special Issue on “Development and Drug Delivery in Epigenetic Therapy”. Epigenetics plays a vital role in regulating DNA without altering the underlying DNA sequence.

Epigenetic regulation occurs through DNA methylation, histone modifications, and interactions with non-coding RNAs, including miRNAs, piRNAs, siRNAs, and long non-coding RNAs. DNA methylation suppresses gene expression, while histone modifications include acetylation, methylation, phosphorylation, and ubiquitylation. Currently, a range of epigenetic drugs, including histone deacetylase inhibitors, have been developed for the treatment of various conditions, such as cancers, central nervous system disorders, and cardiovascular diseases. However, many of these agents face challenges related to solubility, stability, and membrane impermeability. Nanodelivery systems, drug conjugates, and prodrugs may provide promising solutions to these issues. This Special Issue aims to highlight recent progress and emerging trends in this field. We welcome submissions of original research articles focused on the development of epigenetic drugs.

Guest Editor

Dr. Toshihiko Tashima

Tashima Laboratories of Arts and Sciences, 1239-5 Toriyama-cho, Kohoku-ku, Yokohama 222-0035, Japan

Deadline for manuscript submissions

31 May 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/256568

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).